Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01145508 · ClinicalTrials.gov registry record · Phase 2
Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT01145508: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT01145508 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01145508, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well docetaxel and prednisone with or without vaccine therapy works in treating patients with hormone-resistant prostate cancer that has spread to other parts of the body. Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Vaccines made from an antigen may help the body build an effective immune response to kill tumor cells. It is not yet known whether docetaxel and prednisone are more effective with or without vaccine therapy in treating prostate cancer.
Interventions
- DRUG Docetaxel
- OTHER Laboratory Biomarker Analysis
- DRUG Prednisone
- BIOLOGICAL Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine
- BIOLOGICAL Rilimogene Galvacirepvec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2010-08 |
| Est. Completion | 2015-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01145508
The ClinicalTrials.gov registry entry for NCT01145508 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Docetaxel is the first listed.
NCT01145508 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01145508 about?
NCT01145508 is a clinical study titled "Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer". This randomized phase II trial studies how well docetaxel and prednisone with or without vaccine therapy works in treating patients with hormone-resistant prostate cancer that has spread to other parts of the body. Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways ...
What is the current status of trial NCT01145508?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2010-08. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01145508?
The interventions under investigation include: Docetaxel (DRUG), Laboratory Biomarker Analysis (OTHER), Prednisone (DRUG), Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine (BIOLOGICAL), Rilimogene Galvacirepvec (BIOLOGICAL).
Who is sponsoring clinical trial NCT01145508?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.